图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
医药载体系统评论综述
影响因子: 2.9 5年影响因子: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN 打印: 0743-4863
ISSN 在线: 2162-660X

医药载体系统评论综述

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018024397
pages 239-276

Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs

Tulshidas S. Patil
School of Pharmacy and Technology Management, SVKM's NMIMS, Shirpur, Maharashtra, India
Ashwini Deshpande
School of Pharmacy and Technology Management, SVKM's NMIMS, Shirpur, Maharashtra, India
Pravin K. Shende
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai, Maharashtra, India
Shirish Deshpande
School of Pharmacy and Technology Management, SVKM's NMIMS, Shirpur, Maharashtra, India
Ram Gaud
School of Pharmacy and Technology Management, SVKM's NMIMS, Shirpur, Maharashtra, India

ABSTRACT

Pulmonary tuberculosis (TB) is a leading cause of death worldwide and is caused by the pathogen Mycobacterium tuberculosis (MTb). As treatment for TB, dry powders for inhalation (DPIs) are considered stable compared with nebulizers and metered dose inhalers and are suitable for high-dose formulations. Although extensive research has been done over the last two to three decades on nanocarrier-based DPIs for targeting MTb infection, none of the anti-TB DPI formulations have reached the market. Challenges in the proper assessment of nanocarrier-based DPIs due to the complexity of lungs is one of the reasons. In this review, the details of in vitro evaluation parameters of nanocarriers and nanocarrier-based DPIs along with their need and basic principles are discussed. Further, the thorough in vitro, ex vivo, and in vivo pharmacological evaluations, together with their procedures wherever required, are covered. The different evaluation parameters during process development, release specifications, and stability studies suggested by U.S. Food and Drug Administration Center for Drug Evaluation and Research to apply for new drug applications and abbreviated new drug applications of DPIs are also discussed. Lastly, the evaluation parameters for DPIs provided in European, United States, British, and Indian pharmacopeias are summarized.


Articles with similar content:

Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Mradul Mohan, Imran Mohammad, Atul Kumar Agrawal, Sanketkumar M. Pandya, Amit Misra, Anuradha Gupta
Recent Advances in Research of Pharmacology and Clinical Applications of Ganoderma P.Karst. Species (Aphyllophoromycetideae) in China
International Journal of Medicinal Mushrooms, Vol.1, 1999, issue 1
Geng Tao Liu
Strategies and Therapeutic Opportunities for the Delivery of Drugs to the Esophagus
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 3
Hannah Batchelor, Liang Zhang, Barbara R. Conway, Danielle Russell
In Situ Forming Depot as Sustained-Release Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 2
Vivek Ranjan Sinha, Navjot Kanwar
Long-Acting Injectables: Current Perspectives and Future Promise
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 2
Komal Chaudhary, Mayur M. Patel, Priti J. Mehta